GSK acquires RAPT Therapeutics

GSK agreed to acquire RAPT Therapeutics. Reported deal value: $2.2B. Status: Pending. Sector: biopharmaceutical. Target headquarters context: South San Francisco, California, United States.

This page summarizes publicly available information about the transaction as of 2026-01-20. Figures and status may change as filings and press coverage update.

GSK entered into a definitive agreement to acquire RAPT Therapeutics , including RAPT long-acting anti-immunoglobulin E monoclonal antibody,ozureprubart, currently in phase IIb clinical development for prophylactic protection against food allergens.1 As of January 20, 2026, IgE is the only approved systemic therapy that has displayed the ability to protect patients from both a harmful allergic and inflammatory immune response.1 IgE is a clinically validated target with around 94% of severe food allergies being caused by IgE-mediated reactions.1 We are excited to enter into this agreement wi...